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Malignancies involving the upper gas-
trointestinal tract (esophagus, gastric,
biliary, liver, and pancreas) represent
some of the most biologically aggressive
and therapeutically challenging cancers.
In the United States, the number of
patients diagnosed with these cancers in
2003 has been estimated at 70,000 with
approximately 54,000 deaths. Pancreatic
cancer alone will account for 30,000
deaths this year and remains one of the
most treatment-refractory cancers
despite aggressive use of conventional
modalities such as surgery, radiation
therapy, or chemotherapy.
Originally described in Drosophila,
the hedgehog (Hh) signaling pathway is
one of the most fundamental in embry-
onic development. Three mammalian Hh
genes have been identified (sonic Hh
[SHh], Indian Hh [IHh], and desert Hh
[DHh]). Generally, this signal transduc-
tion pathway is responsible for patterning
numerous structures including the axial
skeleton, neural tube, limbs, lungs, skin,
hair, and teeth. In addition, SHh has
been demonstrated to be essential to
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hedgehog signaling pathway in upper gastrointestinal cancers
The hedgehog (Hh) signaling pathway plays many roles in invertebrate and vertebrate development. For example, specific
inhibition of sonic Hh expression is critical during early stages of pancreas organogenesis, but an active Hh pathway
appears to be required for maintenance of adult endocrine functions. Mutational inactivation of the Hh pathway has been
demonstrated in human malignancies of the skin, cerebellum, and skeletal muscle. Now, two papers implicate aberrant Hh
signaling in human upper gastrointestinal cancers including those developing from the esophagus, stomach, biliary tract,
and pancreas.
the mRNA cap binding translation initia-
tion factor eIF-4E (Gingras et al., 2001).
Strikingly, ectopic expression of eIF-4E
is sufficient to phenocopy the ability of
activated Ras to transform primary
rodent cells in cooperation with Myc or
E1A (Lazaris-Karatzas and Sonenberg,
1992). eIF-4E is inhibited by binding to
4E-BP and a set of related proteins, and
this inhibition is relieved by Akt signaling
through mTOR at the level of 4E-BP
phosphorylation (Gingras et al., 1999).
eIF-4E and 4E-BP have opposing effects
on apoptosis, including roles in
mediating the antiapoptotic effects of
activated Ras (Polunovsky et al., 1996,
2000). Interestingly, recent work 
suggests that malignant transformation 
may be associated with a higher require-
ment for cap-dependent translation to
inhibit apoptosis (Li et al., 2002). The
Akt/mTOR pathway also activates the
key translational regulatory kinase
p70S6K (Jefferies et al., 1997), and the
ability of Akt to transform cells is tightly
linked to upregulation of p70S6K and
downregulation of 4E-BP (Aoki et al.,
2001). Taken together, these and other
studies reveal a causal association
between cell transformation and transla-
tional control by Ras/Akt signaling.
Holland and colleagues advance the
association between Ras/Akt signaling
and translation in cancer cells in two
ways: first, by showing that Ras/Akt sig-
naling rapidly influences the patterns of
mRNA loading on polysomes and sec-
ond, by defining the identity of a large set
of genes that are regulated in this man-
ner. As many receptor signaling path-
ways impinge on Ras and Akt, and
thereby on translation initiation factors, it
will be interesting to learn how much
overlap there may be in the genes sub-
jected to regulation at the level of polyso-
mal mRNA recruitment. Furthermore,
given the rapidity with which cells can
respond to signaling through this level of
regulation, it will be interesting to learn
whether other signal transduction path-
ways use the same mechanism to drive
transcription-independent programs of
gene expression.
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normal foregut development, and SHh
null mice show esophageal atresia/steno-
sis, tracheoesophageal fistula, and lung
abnormalities. An Hh signaling model
has been formulated based on studies in
vertebrate systems (Figure 1). Hh pro-
teins bind to a 12-pass transmembrane
protein patched (PTCH), which is the lig-
and binding component of the receptor
complex and functions as a repressor of
the pathway. SHh binding to PTCH
relieves inhibition of smoothened
(SMOH), which is a 7-pass transmem-
brane protein with homology to G 
protein-coupled receptors and is respon-
sible for transducing the Hh signal. In the
absence of Hh binding, PTCH maintains
SMOH in an inactive state, thus inhibiting
signaling to downstream proteins. With
the binding of Hh, PTCH inhibition of
SMOH is released and the signal is
transduced. This results in upregulation
of SHh transcriptional targets, including
PTCH itself as well as members of the
vertebrate GLI family of zinc-finger tran-
scription factors. GLI proteins mediate
the transcriptional program of Hedgehog
signaling (Ingham and McMahon, 2001;
Ruiz i Altaba et al., 2002). Recent stud-
ies have suggested that multiple signal-
ing pathways, including TGF-β, FGF,
notch, and Hh pathways regulate and
interact with each other to govern GI
tract and pancreas development.
Although the exact roles of each Hh lig-
and in pancreas development continue
to be elucidated, it has been demonstrat-
ed that SHh-induced signals block pan-
creas development, whereas the other
Hh ligands appear to control β cell devel-
opment and may function at later stages
in mature pancreatic tissue (Hebrok,
2003).
The importance of the Hh signaling
pathway in tumorigenesis was initially
suggested by the identification of the
Gli1 gene for its involvement in glioma
formation, the Wn1 gene in murine mam-
mary tumorigenesis, and the Smad
genes in the formation of a range of
tumor types and was firmly established
through the discovery of inactivating
mutations in the PTCH gene in patients
with familial and sporadic basal cell car-
cinoma. Other tumors that carry PTCH
mutations include esophageal squa-
mous cell sarcomas and transitional cell
carcinomas of the bladder (Aboulkassim
et al., 2003). Cancer-associated alter-
ations have also been demonstrated for
other components of the Hh signaling
pathway, including activating mutations
in the SMOH gene, and, based on the
role of SHh in lung development, Hh sig-
naling pathway has been demonstrated
to be active in a subset of small cell lung
cancers (Watkins et al., 2003).
Two recent studies published in
Nature extend the concept that Hh sig-
naling is activated in human cancer.
These two studies provide evidence that
overexpression of SHh with subsequent
activation of SMOH can result in a can-
cer-inducing phenotype in some gas-
trointestinal cancers that mimics
inactivation of PTCH in basal cell carci-
nomas. Berman and colleagues
(Berman et al., 2003) demonstrated that
Figure 1. Hedgehog signaling, carcinogenesis, and potential therapeutic targets
Upregulation of Hh ligands may be mediated by epigenetic events. Mutations in PTCH and SHOH result in activation of hedgehog signaling and
are causative in basal cell carcinoma and medulloblastoma. Gli proteins are thought to mediate activation of Hh transcriptional targets poten-
tially important in tumorigenesis, progression, and metastasis. Abbreviations: SHh, sonic hedgehog; IHh, Indian hedgehog; DHh, desert hedge-
hog; HIP, hedgehog interacting protein; PTCH, patched; SMOH, smoothened; GLI; cubitus interruptus-like transcription factor involved in glioma
formation.
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upper gastrointestinal malignancies
derived from the esophagus, biliary tract,
stomach, and pancreas display increased
Hh pathway activity. Further, they
showed that cell growth was mediated by
endogenous expression of Hh ligands
through demonstration of the growth
inhibitory activity of Hh-neutralizing anti-
body and the growth stimulatory activity
of exogenously added Hh ligand. Finally,
cyclopamine, a steroidal alkaloid that
inhibits Hh signaling through direct inter-
action with SMOH, was shown to sup-
press cell growth in vitro and produce
durable regression of a cholangiocarci-
noma cell line in vivo.
The observations of Berman et al. on
pancreatic cancer cell lines have been
amplified through the work of Thayer and
colleagues (Thayer et al., 2003). These
investigators demonstrated that SHh is
abnormally overexpressed in pancreatic
adenocarcinoma cells and pancreatic
intraepithelial neoplastic lesions (PanINs)
compared to normal pancreatic ductal
epithelium. Interestingly, pancreata from
transgenic mice overexpressing SHh dis-
played abnormal tubular structures that
resemble early PanINs, and some of
these PanIN-like lesions also harbored
K-ras mutations and overexpressed
Her2/neu. These later two molecular
abnormalities are characteristic alter-
ations found in early pancreatic ductal
carcinogenesis. Like Berman et al., this
group also found that the Hh signaling
pathway is active in most pancreatic can-
cer cell lines and inhibition of Hh signal-
ing by cyclopamine induced apoptosis
and inhibited proliferation in a subset of
these pancreatic cell lines. The reasons
that some cell lines with apparent activa-
tion of Hh signaling remained resistant to
cyclopamine are still unclear but will be
important to understand as efforts pro-
ceed to target the Hh pathway for drug
development.
The significance of these two papers
cannot be underestimated. While further
delineation of the role of Hh signaling in
upper gastrointestinal cancers needs to
proceed, it is apparent that this signal
transduction pathway has relevance to a
large group of human cancers providing
new opportunities for the identification
and subsequent validation of therapeutic
targets. In addition, the suggestion that
aberrant Hh signaling is an early event in
pancreatic carcinogenesis opens oppor-
tunities to develop techniques to detect
aberrant Hh signaling in pancreatic juice
or pancreatic duct cytology specimens
for the early diagnosis of premalignant
PanINs.
Successfully targeting Hh signaling
will require further insights into the role
of this pathway in cancer. First, we will
need to understand how altered Hh sig-
naling contributes to carcinogenesis.
Currently, we have very little perception
of the underlying mechanisms that link
these two processes. Second, there may
be only subsets of GI cancer patients
with dysregulated Hh pathways. Third,
there may be redundancy and crosstalk
within the Hh signaling pathway that may
prevent biologically effective blockade
(Grachtchouk et al., 2003; Weiner et al.,
2002). And finally, Hh signaling may be
critical to other normal physiologic
processes such as tissue repair (Watkins
et al., 2003). Nevertheless, the apparent
requirement for Hh pathway activation in
an important group of human cancers
represents a potential therapeutic oppor-
tunity (Berman et al., 2002; Williams et
al., 2003) that warrants further investi-
gation.
In a broader sense, the observation
that Hh signaling pathways are activated
in some cancers supports the growing
appreciation that the signaling pathways
that control vertebrate embryonic devel-
opment may also be important during
human carcinogenesis. The observa-
tions that the Hh signaling pathway is
activated in esophageal, gastric, biliary
tract, and pancreatic cancers provides
important new opportunities for the
development of novel interventions that
may be applicable to a large group of
cancer patients who currently have only
limited therapeutic options.
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